Getting it into people's hands is another thing entirely
At the intersection of neuroscience and human dignity, Control Bionics has welcomed Professor Nicholas Opie — co-founder of Synchron and architect of endovascular brain-computer interfaces — to its board of directors. The appointment reflects a broader moment in which the long-promised convergence of neural engineering and assistive technology is beginning to move from laboratory ambition into lived reality. For people living with paralysis or severe movement limitations, such institutional commitments carry weight that extends well beyond corporate strategy.
- People with severe movement limitations still face profound barriers to communication — barriers that neuroelectric signal technology is only beginning to dismantle at scale.
- Control Bionics is pushing into North American, European, and Japanese markets simultaneously, a multi-front expansion that demands both scientific credibility and strategic precision.
- Opie's arrival — carrying the intellectual weight of Synchron's Stentrode, 60-plus peer-reviewed papers, and a deep patent portfolio — gives the company a rare combination of academic authority and commercial translation experience.
- The NeuroNode and NeuroStrip platforms are already in the hands of users, but the harder challenge now is building the partnerships and distribution networks that turn promising devices into widely accessible tools.
- The retirement of Dr Stephanie Phillips closes one chapter of governance even as Opie's four-year vesting structure signals the board's commitment to a long, deliberate arc of growth.
Control Bionics has appointed Professor Nicholas Opie as Non-Executive Director and strategic advisor, a move the company's leadership believes will sharpen its trajectory in neuroelectric signal technology. The appointment comes as the company deepens its presence across assistive communication, rehabilitation, sports performance, and broader neurotechnology markets.
Opie's credentials are formidable. He co-founded Synchron, the company behind the Stentrode — an endovascular brain-computer interface that reads neural signals from blood vessels to let people with paralysis control digital devices. He also co-founded Ultra Bionics, focused on minimally invasive ultrasonic deep brain neuromodulation, and leads the Vascular Bionics Laboratory at the University of Melbourne. His body of work spans more than 60 peer-reviewed papers and a patent portfolio covering neural interfaces, endovascular sensing, and closed-loop neuromodulation systems.
Chairman Stephen Rix described the appointment as both a validation of the company's science and a catalyst for its next phase of development. Opie will work alongside the board, management, and technical teams to identify new market opportunities and guide technology strategy. He expressed genuine enthusiasm for helping bring Australian-developed assistive tools to a global audience.
At the heart of the company's offering are two platforms: the NeuroNode, a wearable that captures faint EMG signals from muscles and combines them with eye gaze and touch input to enable faster, less fatiguing communication for people with severe movement limitations; and the NeuroStrip, a smaller device opening pathways into diagnostics, sports monitoring, and rehabilitation. Distribution is expanding across North America, Australia, Europe, and Japan. Shareholders will be asked to approve the issuance of 1.25 million options to Opie, vesting equally over four years.
The appointment also marks the immediate retirement of Non-Executive Director Dr Stephanie Phillips, whose contributions spanned medical, academic, and governance dimensions. Opie's arrival signals that Control Bionics is moving past proof-of-concept into the more demanding work of scaling — finding the right partners, the right markets, and the right paths to reach the people these technologies were built to serve.
Control Bionics has brought on Professor Nicholas Opie as a Non-Executive Director and strategic advisor, a hire the company's board believes will accelerate its work in neuroelectric signal technology. The appointment arrives as the company pushes deeper into markets for assistive communication, rehabilitation, sports performance, and broader neurotechnology applications.
Opie carries substantial weight in the field. He co-founded Synchron, the company behind the Stentrode—an endovascular brain-computer interface that allows people with paralysis to control digital devices by reading neural signals directly from blood vessels in the brain. He also co-founded Ultra Bionics, which is developing minimally invasive ultrasonic deep brain neuromodulation, and he directs the Vascular Bionics Laboratory at the University of Melbourne. His publication record spans more than 60 peer-reviewed papers, and his patent portfolio covers neural interfaces, endovascular sensing and stimulation, and closed-loop neuromodulation systems—the kind of technical depth that signals serious credibility in a field still finding its footing.
Control Bionics chairman Stephen Rix framed the appointment as validation of the company's underlying science and the range of problems it might solve. Rix said Opie would work directly with the board, management, and technical teams to shape the next phase of the company's technology development and identify new market opportunities. Opie himself expressed enthusiasm for supporting the team as it takes Australian-developed assistive communication and rehabilitation tools into global markets.
The company manufactures two core platforms. The NeuroNode is a wearable device that captures extremely small electrical signals from muscles—EMG signals—and combines them with eye gaze and touch input to enable faster, less tiring communication for people with severe movement limitations. The NeuroStrip, a smaller version, opens doors into diagnostics, sports performance monitoring, and rehabilitation, and the company is expanding distribution into North America, Australia, Europe, and Japan. As part of Opie's engagement, the board has resolved to seek shareholder approval to issue him 1.25 million options vesting equally over four years and expiring in May 2031.
The move also marks the retirement of Non-Executive Director Dr Stephanie Phillips, effective immediately, after contributions to the company's medical, academic, and governance work. Opie's arrival signals that Control Bionics is moving beyond proof-of-concept into the harder work of scaling—finding the right markets, building the right partnerships, and translating laboratory success into devices that actually reach the people who need them.
Citas Notables
Opie's decision to join reflected confidence in the company's science and the breadth of its potential applications— Stephen Rix, Control Bionics chairman
Excited to support the team as it advances Australian-developed assistive communication, rehabilitation, sports performance and broader neurotechnology applications for global markets— Professor Nicholas Opie
La Conversación del Hearth Otra perspectiva de la historia
Why does a company like Control Bionics need someone like Opie on the board? Isn't the science already proven?
The science is one thing. Getting it into people's hands is another. Opie has done both—he's built companies, gotten devices through regulatory approval, and scaled them internationally. That's rare.
What makes the Stentrode different from other brain-computer interfaces?
Most BCIs require surgery to implant electrodes directly into the brain tissue. The Stentrode goes through the blood vessels instead—less invasive, fewer complications, faster recovery. It's elegant engineering.
And Control Bionics doesn't do that. They use muscle signals instead.
Right. Different approach, different problem it solves. The NeuroNode captures the tiny electrical signals your muscles still produce, even when you can't move. For someone with locked-in syndrome or severe ALS, that's enough to communicate.
So why bring in someone whose expertise is in invasive neural interfaces?
Because Opie understands the whole ecosystem—regulatory pathways, clinical validation, how to talk to hospitals and insurance companies. He's seen what works and what doesn't. That knowledge transfers.
Is this about Control Bionics pivoting toward more invasive technology?
Not necessarily. It's about having someone at the table who can help them think bigger about what their platform could become, and how to position it against competitors who are doing more invasive things.
What's the real test now?
Whether they can actually scale into those new markets—North America, Europe, Japan. The technology works. The question is whether it can compete on price, reimbursement, and clinical adoption. That's where Opie's experience matters most.